Treatment of (unresectable) hepatocellular carcinoma at an intermediate or advancedstage;Traitement des carcinomes hépatocellulaires à un stade intermédiaire ou avancé

Revue Medicale de Liege

Volumn 64, Issue 3, 2009, Pages 140-147

  Van Daele, D ^a   Belaiche, J ^b   Delwaide, J ^b   Piront, P ^b   De Roover, A ^b   Detry, O ^b   Honore P ^b   Polus, M ^b  

^a HIS   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Barcelona clinic liver; Hepatocellular carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBAMAZEPINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; INTERFERON; IODINATED POPPYSEED OIL I 131; IRINOTECAN; NOLATREXED; OCTREOTIDE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; WARFARIN; YTTRIUM 90;

ADVANCED CANCER; ALOPECIA; ANOREXIA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; DEVELOPING COUNTRY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; TUMOR VOLUME; LIVER TUMOR; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 63849218163     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Bosch FX, Ribes J, Borras J.- Epidemiology of primary liver cancer. Semin Liver Dis, 1999, 19, 271-285.
2. Chang MH, Chen CJ, Lai MS, et al.-Universal hepatitis B vaccination in Taiwan and the incidence of hepato-cellular carcinoma in children. N Engl J Med, 1997, 336, 1855-1859.
3. Chang MH, Shau WY, Chen CJ, et al.- The Taiwan Childhood Hepatoma Study Group. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Assoc, 2000, 284, 3040-3042.
4. El-Serag HB, Rudolph KL.- Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.
5. Chevret S, Trinchet JC, Mathieu D, et al.- A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol, 1999, 31, 133-141.
6. Garcia-Tsao G.- Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology, 2001, 120, 726-748.
7. El Serag HB, Mason AC.- Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999, 340, 745-750.
8. Van Vlierberghe H, Borbath I, Delwaide J, et al. (BASL HCC working group) and the BASL steering commi- tee.- BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gas- troenterl Belg, 2004, 67, 14-25.
9. A Grieco, M Pompili, G Caminiti, et al.- Factors for survival in patients with early-intermediate hepatocel- lular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP and BCLC staging in a single Italian centre. Gut, 2005, 54, 411-418.
10. Llovet JM, Bru C, Bruix J.- Prognosis of hepatocellu- lar carcinoma: the BCLC staging classification. Semin Liver Dis, 1999, 19, 329-338.
11. Cillio U, Vitale A, Grigoletto F, et al.- Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol, 2006, 44, 630-632.
12. Llovet JM, Fuster J, Bruix J.- Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology, 1999, 30, 1434 -1440.
13. Colle I, Orient H, Delwaide J.- Discussion on the risk of surgery in patients with cirrhosis. Acta Gastroenterl Belg, 2008, 71, 47.
14. Llovet JM, Beaugrand M.- Hepatocellular carcinoma: present status and future prospects. J Hepatol, 2003, 38, S136-S149.
15. Arii S, Yamaoka Y, Futagawa S, et al.- Results of surgical and nonsurgical treatment for small-sized hepa- tocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology, 2000, 32, 1224-1229.
16. Adler M, Lerut J, Starkel P, et al.- Outcome of patient with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transplant, 2008, 14, 526-533.
17. Mazzaferro V, Regalia E, Doci R, et al.- Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334, 693-699.
18. Bismuth H, Majno PE, Adam R.- Liver transplantation for hepatocellular carcinoma. Semin Liver Dis, 1999, 19, 311-322.
19. Lau WY, Leung TW, Ho SKW, et al.- Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepa- tocellular carcinoma: a prospective randomised trial. Lancet, 1999, 353, 797-801.
20. Mazzafero V, Romito R, Colombo M, et al.- Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report (abstract). J Hepatol, 2004, 40 ( suppl 1), 34 A.
21. Shiratori Y, Shiina S, Teratani T, et al.-Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med, 2003, 138, 299-306.
22. Llovet JM, Moitinho E, Sala M, et al.- Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients with spontaneous bacterial peritonitis. J Hepatol, 2000, 33, 423-429.
23. Bruix J, Llovet JM.- Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 2002, 35, 519-524.
24. Llovet JM, Bustamante J, Castells A, et al.- Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 1999, 29, 62-67.
25. Porta C, Ruff P, Feld R, et al.- Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX). Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, Florida, January 24-26,2006.
26. Yeo W, Mok TS, Zee B, et al.- A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 2005, 97, 1532-1538.
27. Llovet JM, Ricci S, Mazzaferro V, et al.- Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359, 378-390.
28. Lin DY, Liaw YF, Lee TY, et al.- Hepatic arterial embo- lization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology, 1988, 94, 453-456.
29. Pelletier G, Roche A, Ink O, et al.- A randomized trial of hepatic arterial chemoembolization in patients with unre- sectable hepatocellular carcinoma. J Hepatol, 1990, 11,181-184.
30. Groupe d'Etude et de Traitement du Carcinome Hepato- cellulaire.-A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellu- lar carcinoma. N Engl J Med, 1995, 332, 1256-1261.
31. Bruix J, Llovet JM, Castells A, et al.- Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepato- logy, 1998, 127, 1578- 1583.
32. Pelletier G, Ducreux M, Gay F, et al.- Treatment of unresectable hepatocellular carcinoma with lipiodol che- moembolization: a multicenter randomized trial. J Hepa- tol, 1998, 29, 129-134.
33. Lo CM, Ngan H, Tso WK, et al.- Randomized controlled trial of transarterial lipiodol chemoembolization for unre- sectable hepatocellular carcinoma. Hepatology, 2002, 35,1164- 1171.
34. Llovet JM, Real MI, Montana X, et al.- Arterial embo- lisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359, 1734-1739.
35. Llovet JM, Bruix J.- Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma. Chemoembolization improves survival. Hepato-logy, 2003, 37, 429-442.
36. Doffoel M, Vetter D, Bouché O, et al.- La chimioembo- lisation lipiodolee ameliore-t-elle la survie et la qualite de vie des patients ayant un carcinome hépatocellulaire surcirrhose ? Resultats d'un essai prospectif, randomise et multicentrique (FFCD 9402) (abstract). Gastroenterol Clin Biol, 2005, 29, A148.
37. Raoul JL, Guyader D, Bretagne JF, et al.- Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis : intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med, 1994, 35, 1782-1787.
38. Raoul JL, Guyader D, Bretagne JF, et al.- Prospective randomized trial of chemoembolization versus intra-ar- terial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology, 1997, 26, 1156-1161.
39. Salem R, Hunter RD.- Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int JRadiat Oncol Biol Phys, 2006, 66, S83-S88.
40. Burroughs A, Hochhauser D, Meyer T.- Systemic treatment and liver transplantation for hepatocellular carcinom: two ends of the therapeutic spectrum. Lancet Oncol, 2004, 5, 409-418.
41. Porta C, Ruff P, Feld R, et al.- Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX). Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, Florida, January 24-26, 2006.
42. Yeo W, Mok TS, Zee B, et al.- A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 2005, 97, 1532-1538.
43. Barbare JC, Bouche O, Bonnetain F, et al.- Randomized controlled trial of tamoxifen in advanced hepatocel-lular carcinoma. J Clin Oncol, 2005, 23, 4338-4346.
44. Grimaldi C, Bleiberg H, Gay F, et al.- Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol, 1998, 16, 411-417.
45. Groupe d'Etude et de Traitement du Carcinome Hepa- tocellulaire. - Randomized trial of leuprorelin and flu- tamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology, 2004, 40, 13611369.
46. Llovet JM, Sala M, Castells L, et al.- Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology, 2000, 31, 54-58.
47. Yuen MF, Poon RT, Lai CL, et al.- A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepa-tology, 2002, 36, 687-691.
48. Barbare JC, Bouche O, Bonnetain F, et al.- Résultats de l'essai multicentrique randomisé en double-aveu- gle octreotide-retard versus placebo pour le traitement palliatif du carcinome hepatocellulaire : etude CHOC FFCD-ANGH 2001-01(abstract). Gastroenterol Clin Biol, 2005, 29, A88.
49. Verset G, Verslype C, Reynaert H, et al.- Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomized multicentre phase III study. Br J Cancer, 2007, 97, 582-588.
50. Adnane L, Trail PA, Taylor I, et al.- Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol, 2005, 407, 597- 612.
51. Abou-Alfa GH, Schwartz L, Ricci S, et al.- Phase II study of sorafenib in patients with advanced hepatocel- lular carcinoma. J Clin Oncol, 2006, 24, 4293-4300.
52. Detry O, Delwaide J, De Roover A, et al.- L'etude clinique du mois. Traitement de l'hepatocarcinome au stade palliatif par sorafénib (Nexavar®). Résultats de l'étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol). Rev Med Liege, 2009, 64,168-170.
53. Bolondi L, Caspary W, Bennouna J, et al.- Clinical benefit of sorafénib in hepatitis C patients with hepa- tocellular carcinoma (HCC) : Subgroup analysis of the SHARP trial. Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, Florida, January, 2008. Abstract No: 129.
54. Thésaurus National de Cancérologie Digestive. www.snfge.asso.fr/01-Bibliotheque/0G-Thesaurus-cancerologie/publication5/ sommaire-thesaurus.asp Recommandations PRODIGE AFEF pour l'utilisation du sorafénib www.snfge.org/01-Bibliotheque/0D-Prati- ques-cliniques/Reco- hors-HAS/reco-sorafenib.pdf
55. Malka D, Dromain C, Farace F, et al.- Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol, 2007, 25, 215s.
56. Schwartz JD, Schwartz M, Lehrer D, et al.- Bevaci- zumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol, 2006, 24, 213s.
57. Sun W, Haller DG, Mykulowycz K, et al.- Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. J Clin Oncol, 2007, 25, 216s.
58. Hewitt MR, Sun W, HallerDG, et al.- A phase II trial of combination of capecitabine, oxaliplatin with bevacizu- mab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis. J Clin Oncol, 2006, 24 (suppl 18), 631s.
59. Philip PA, Mahoney MR, Allmer C, et al.- Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol, 2005, 23, 66576663.
60. Thomas MB, Chadha R, Iwasaki M, et al.- The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol, 2007, 25(suppl 18), 214s.